The term 'cerebral palsy' (CP) stands for a wide group of disorders of motor and postural development, caused by nonprogressive lesions occurring in the fetal or infant brain. 1, 2 According to the Surveillance of Cerebral Palsy in Europe, [1] [2] [3] [4] [5] CP can be classified into three main subgroups, on the basis of the predominant clinical features: spastic (which accounts for the 85%-90%), dyskinetic (between 6.5% and 14.4%), and ataxic (up to 4% of the total CP population). [4] [5] [6] [7] The nosography of movement disorders in CP shows slight but significant differences in terminology if compared with classical, adult neurology, and this has been an important confounding factor in the past. According to Surveillance of Cerebral Palsy in Europe, dyskinetic CP is characterized by the presence of involuntary, disorganized, and often stereotyped movements, associated with a fluctuating muscular tone. It may be further defined as 'dystonic' or 'choreoathetotic': in the dystonic type, the predominant state of involuntary muscular co-contraction and hypertonia leads to sustained or intermittent, twisting, and repetitive movements and/or postures of trunk, arms and legs; the choreoathetotic type is characterized by the prevalence of distal and/or proximal hyperkinetic movements, often associated with hypotonia. [1] [2] [3] [4] 7 Both dystonia and choreoathetosis can occur either at rest and/or during action or specific tasks, and usually coexist in patients with dyskinetic CP. This may represent a very disabling burden in terms of impairment of motor abilities, postural discomfort, and painful contractions, affecting the quality of life of both patients and caregivers. Dystonia and choreoathetosis in CP might respond differently to different drugs, but much more has to be done in the understanding of their physiopathology. Moreover, the additional presence of spasticity makes the choice of the pharmacological therapy even more challenging.
Although data on the efficacy of new treatments for movement disorders, such as intrathecal baclofen, botulinum toxins, and deep brain stimulation, [8] [9] [10] [11] [12] [13] have progressively increased over the past two decades, evidence on the efficacy of the first-line oral medications in dyskinetic CP still remains unclear. This has led to the lack of specific guidelines in clinical practice and the selection of drugs is actually based on expert opinions or individual clinical experience, rather than on exhaustive scientific data. A partial explanation for this may be found in the difficulty of defining and classifying dyskinetic CP and their complex features, as well as in the absence of reliable disease-specific outcome measures, able to detect significant clinical changes when testing the efficacy of an investigational product in a pharmacological clinical trial. Until recent years, only three rating scales assessing dystonia were available: 14 the Barry-Albright Dystonia Scale (the only one specifically addressed to secondary dystonia), 15 the Burke-Fahn-Marsden Scale, 16 and the Unified Dystonia Rating Scale. 17 Unfortunately, despite their good reliability, these scales were developed before the most recent definitions of dystonia and choreoathetosis in CP, were validated in cohorts including adult patients, and cannot disclose in detail the different characteristics composing the movement disorder in this condition. More recently, two new standardized rating scales for the assessment of genetic and acquired movement disorders in the paediatric population have been proposed, whose sensitivity in detecting drug efficacy is under development.
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The present systematic review aims to examine the actual level of evidence on the efficacy of oral medications in the management of dyskinetic CP, considering treatments for both dystonia and choreoathetosis. Drug efficacy in improving motor and/or functional outcomes, and in reducing movement disorders, will be discussed in the light of the evolving classification of dystonic syndromes and dyskinetic movement disorders in CP.
METHOD
The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews (PRISMA) statement, 23 and following the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) methodology for the systematic reviews. 24 The review covers data available up to December 2016. A first explorative search was conducted to find reviews and original articles dealing with similar subjects, and to identify candidate search terms. Selected key words were combined to create search strategies, adjusted for each screened database. References from relevant articles and reviews were searched for inclusion of additional papers not previously identified through the systematic search. (Fig. 1) . Search terms included: 'cerebral palsy', 'oral drug/therapy/ medication' OR 'pharmacotherapy' OR 'medical treatment', in addition to references to specific active principles. Search strategies and search terms (PubMed, Scopus, Web of Science, and Cochrane Library) are reported in the online supporting information (Table SI) .
The systematic search was organized according to PICOS framework (i.e. patient, intervention, comparison, outcome, study design), and data were extracted from each article according to the AACPDM 'summary form', as follows. (1) Population: 'cerebral palsy'. We considered only studies specifically addressed to the dyskinetic forms of CP, excluding those primarily focused on spasticity (even if associated with extrapyramidal disorders), hypertonia, or drooling. (2) Interventions: 'medical therapy'. We considered only oral drugs, and excluded intrathecal baclofen, botulinum toxins, any invasive treatment such as deep brain stimulation or pallidotomy, and combined therapies. (3) Outcomes: studies had to give information on motor and/or functional outcomes after treatment, according to one or more dimensions of the International Classification of Functioning, Disability and Health: Children & Youth Version (ICF-CY) (i.e. body functions and structures, activities, participation, and contextual aspects). 25 Measures of dystonia and choreoathetosis, or overall motor improvement after drug administration, either by clinical examination or standardized scales (e.g. Burke-Fahn-Marsden Dystonia Scale, Barry-Albright Dystonia Scale, and others) were considered.
Eligibility
Studies were considered eligible for the qualitative analysis if the participants were affected with dyskinetic CP. In studies considering different subtypes of CP, when a clear distinction between groups was not possible, patients with the dyskinetic forms had to represent more than 50% of the sample. When only a few patients presented with dyskinetic CP (<50% of the sample), studies were included if clear outcome measures were available for each patient. In older articles, in which the definition 'dyskinetic cerebral palsy' was not used, similar terms could be found (e.g. 'athetoid', 'dystonic', or 'choreoathetotic' CP). Other secondary dystonias were not considered in this review (e.g. postencephalitic or poststroke syndromes). A minimum duration of the study was not required. Adverse events were considered when available.
According to the AACPDM methodology, case reports, observational studies, and randomized clinical trials were included. Only papers published in peer-reviewed journals and in the English language were assessed, without limitations regarding the year of publication.
The articles were examined by the three authors, and eligibility for study inclusion was assessed independently;
What this paper adds
• Evidence to prove (or disprove) the efficacy of oral drugs in dyskinetic cerebral palsy is low.
• The most investigated drugs, trihexyphenidyl and levodopa, show contradictory results.
• Tetrabenazine, levetiracetam, and gabapentin efficacy should be studied in more detail.
• Lack of evidence is partially due to the inconsistency of classifications and outcome measures used.
• Outcome measures should be selected within the framework of the International Classification of Functioning, Disability and Health in next clinical trials.
in case of discordant opinion between the reviewers, the eligibility of the study was discussed until consensus was reached. The quality of evidence was scored according to the AACPDM approach, for both single-subject research and group research studies (Table SII, online supporting information).
RESULTS

Overview of published articles
The current classification of CP was adopted only after 2000, thanks to the work of the European network of CP surveys and registers. 5 Before that, several definitions were used to describe clinical features of patients with CP, making a direct comparison between oral drugs in specific subtypes of CP challenging. The systematic search identified 41 original papers ( Fig. 1 ; Table SIII, online supporting information), reporting on 22 different drugs. Only 28 articles were in English. Eleven studies were defined as double-blind clinical trials, five were open-label trials (one of which with a second blind part), four were retrospective studies, and seven were case reports or case series. Two papers were conference contributions. Some of these studies have been discussed in a recent systematic review on the treatments of secondary dystonia. 26 Among the different drugs tested over the years in dyskinetic CP, trihexyphenidyl (or other anticholinergic drugs) and levodopa were the most used and the best studied ones. A smaller number of articles reported on tetrabenazine, diazepam, dantrolene, and baclofen. Moreover, we found two papers describing anecdotal cases of unexpected effects of anticonvulsant (carbamazepine) and central nervous system stimulant (methylphenidate) 27 drugs in reducing dyskinetic symptoms in adult patients.
Qualitative analysis of eligible articles
According to the eligibility criteria, 16 articles were selected for further qualitative analysis (Table I) . Eight articles were scored more than III for level of evidence (considering both single-subject research studies and group research studies; see Table SIV for conduct quality rating), and their outcome measures related to ICF components are reported in Table II. Trihexyphenidyl (Artane), an anticholinergic agent, is the most investigated drug for the treatment of dyskinesia in CP in the selected literature. We identified eight studies on trihexyphenidyl (Table I) , all of which aimed to improve the global motor outcome and/or to reduce the burden of movement disorder in patients with dyskinetic CP (age range 0.5-19y, not specified in two studies 28, 29 ). One of them presented a narrower focus on the upper limb function. 30 Despite the fact that some of these studies also investigated non-motor functional outcomes (e.g. Sanger et al., 30 by use of the Pediatric Outcomes Data Collection Instrument, 31 PedsQL, 32 and Care and Comfort Scale), Review 1239 34 the Canadian Occupational Performance Measure and the Goal Attainment Scale. 37, 38 Three studies were randomized, double-blind, controlled trials (level I evidence), 28 ,33,34 one of which described analytically the selection of patients and the randomization method. 34 Seven studies reported the research protocol, with a schedule for dosage in six studies, and the starting and target doses of the drug. Hoon et al. only defined the range of the mean dosage in their retrospective analysis. 39 All studies reported length of treatment, the number of withdrawals, and data on adverse events.
The consistency between studies was very low, owing to differences in inclusion criteria (absence of distinction between choreoathetotic and dystonic features at the screening and between different aetiologies of CP, absence of a stratification for range of age), primary and secondary end points (reduction of dystonia, improvement of motor skills, non-motor functional outcomes), and measures of outcome (different and/or not specific standardized scales, unstructured parental interviews, and clinical examinations).
Taken together, these studies are at least partially contradictory. Four articles (level IV evidence) reported a variable degree of improvement, predominant in upper limb and oromotor functions, although based on different outcome measures. Burke et al. (level I evidence) also found a good response after treatment, but their sample included only two patients with dyskinetic CP. 33 However, the study with the highest level of evidence conducted in a cohort of patients with dyskinetic CP (Rice and Waugh, 34 level I evidence), failed to find any effect Review 1243 on the severity of dystonia and upper limb function in severely affected children. Finally, Sanger et al. described a worsening in patients with choreic or choreoathetotic features during treatment with trihexyphenidyl. 30 All the studies reported typical anticholinergic effects as adverse events, which led to treatment discontinuation only in few cases (Table III) .
Two studies on levodopa met the eligibility criteria. Rosenthal et al. investigated the effects of levodopa in nine patients (seven adults and two adolescents, aged 15-46y) affected by athetoid CP in an open-label trial (level IV evidence), reporting an improvement in motor skills in eight of them, an improvement of speech in six, and pain relief and better mood in six. 40 The results on motor and postural skills were confirmed in a later double-blind, placebocontrolled phase of the study, conducted on the same patients. However, only clinical evaluations were performed in all the participants. Pozin et al. studied nine patients (six children and three young adults, aged 9-24y) affected with CP and upper limb dystonia in a doubleblind, placebo-controlled trial, with the aim to evaluate the improvement in hand function (as measured by Quality of Upper Extremity Test and others manual skills tests). 41 The authors concluded there were no differences between levodopa and placebo (level I evidence). Except for the mean age of the two cohorts, these two studies showed a good consistency in terms of inclusion criteria.
Diazepam is one of the major therapeutic options in children with spastic CP, because of its efficacy in reducing hypertonia. Although diazepam has been reported to also be effective in athetoid patients, we found only one study specifically investigating its efficacy in participants with dyskinetic CP. Angara and Whittaker reported on seven children with 'athetoid CP', clinically evaluated at least 2 months after starting therapy (level IV evidence). 42 A slight improvement was noted in three children, without significant results in the remaining four. Minor adverse events were common and mainly characterized by drowsiness (Table III) .
Tetrabenazine is a benzoquinolone, which acts by depleting presynaptic monoamines and preventing dopamine release from vesicles. 43 Given its weak antagonism on postsynaptic dopamine receptors, it is not responsible for tardive dyskinesia. Notwithstanding the lack of data on paediatric population, the most common and dose-limiting side effects of tetrabenazine in adults are well known, including somnolence, depression, anxiety, and parkinsonism. 43 The efficacy of tetrabenazine in improving hand abilities was investigated by Heggarty and Wright, 44 in a double-blind crossover trial (level I evidence) including 30 children with athetoid CP (age range 3-19y ). An apparent improvement was found both in semi-structured hand function tests and in subjective measures of handwriting or typing and ability to perform daily activities, despite minor changes in overall clinical picture. Drowsiness was the most commonly reported and dose-related adverse event (Table III) . Quite surprisingly, the study by Heggarty and Wright is the only published trial on tetrabenazine in CP patients. 44 The effects of dantrolene sodium (Dantrium), a muscle relaxant, was investigated by Chyatte et al. in 17 patients with athetoid CP (age range 7-38y), in a double-blind, randomized, crossover study (level I evidence). 45 Outcome measures were the overall clinical response and the activities of daily living. An improvement in both was reported for more than half of patients by clinical evaluation and interviews, but none of the objective measures adopted (e.g. Methods-Time Measurement) could quantify the changes. Minimal side effects were reported (Table III) .
Perphenazine (Trilafon, a phenothiazine derivative) and etybenzatropine (Ponalid, an anticholinergic and antihistaminergic drug), were investigated in two different groups of 12 children and 11 children respectively, with athetoid or mixed athetoid and spastic CP (age range 4-17y) in a double-blind study (level I of evidence). 46 None showed satisfactory efficacy. Moreover, perphenazine is a typical antipsychotic drug and, unlike tetrabenazine, it carries a risk of tardive dyskinesia which significantly reduces its potential use in clinical practice.
Finally, two case reports described unexpected effects of methylphenidate and levetiracetam in reducing motor disorder in dyskinetic CP (level V evidence), 27, 47 even though the authors did not hypothesize any underlying biological mechanism for that.
DISCUSSION
In the present systematic review, 16 studies met the eligibility criteria. We found that the overall level of evidence on the efficacy of oral drugs in the management of dyskinetic CP is very low. This is quite surprising, given the time since the first descriptions and the still wide use in clinical practice of oral medications in the treatment of movement disorders in such patients. This lack of evidence is mainly related to the discrepancy of the inclusion criteria among the different studies, and to the unclear motor and/ or functional outcomes investigated, often by means of assessments which were not disease-specific or sufficiently sensitive to change.
The inconsistent inclusion criteria used in most of the reviewed studies are the consequence of a poorly shared classification of the clinical phenotypes composing the umbrella term of 'dyskinetic cerebral palsy'. Until the definition by the Surveillance of Cerebral Palsy in Europe the distinction between 'choreoathetotic components' and 'dystonic features' in such forms of CP was not systematically considered in patient descriptions. [1] [2] [3] [4] This is a core issue, as physiopathological mechanisms underlying such clinical manifestations could respond differently to medications. Choreoathetosis is reported to impact less than dystonia on functional abilities, when severity is similar. 22 This further highlights the need to distinguish the two components of the movement disorder and to define clearly which is the outcome to evaluate when planning an interventional study with oral medications in dyskinetic CP. The classification of mixed dystonic-choreoathetotic phenomenology, which represents the majority of patients with dyskinetic CP, is a core issue and the first challenge to address in future studies.
At the same time, the end points of the reviewed studies, and how the change should be measured, were not always clearly indicated. Additionally, outcomes of interest in the different domains of the ICF were not consistent across the studies. Valid and reliable disease-specific scales for the evaluation of dyskinetic features in CP were not available until recent years. In 2008, Battini et al. proposed a new rating scale aimed to define the functional impairment produced by dystonia and choreoathetosis in childhood movement disorders, together with the severity of the disease. [18] [19] [20] Later, Monbaliu et al. published a different scale with the purpose of distinguishing the choreoathetotic components of the movement disorder from the dystonic ones. 21, 22 As they coexist in the majority of patients, the possibility of 'weighting' each of them in order to choose the better treatment might be useful in clinical practice. Both these new instruments could provide a common and solid basis on which to include more homogeneous patients in future studies, and to evaluate drug efficacy both at the body function and at the activity levels (e.g. improvement of dystonia and/or choreoathetosis, abilities of daily living, voluntary motor skills).
Although the evidence of efficacy of oral drugs in dyskinetic CP is too low to consider any of them as the first recommended approach, some suggestions can be drawn by the selected studies.
Trihexyphenidyl needs further investigation, primarily in dystonic patients with predominant involvement of upper limb. One study with a moderate level of evidence found some improvement in upper limb function after treatment with trihexyphenidyl, 30 but this was not confirmed by other studies. Additionally, the same study reported some worsening when choreoathetotic features were obvious. Several authors suggest to start with a low dosage and slow titration, in order to limit possible adverse events. 29, 33 However, one of the major limitations of the studies on trihexyphenidyl is the use of a low dosage, for a relatively short duration (Table I) . One or 2 months might not be sufficient for titration to an effective dosage, and even at target dosages it might take several weeks to see the effects. Finally, children seem to tolerate a higher dosage than adults, 29 and this has to be taken into account in the design of future studies.
Tetrabenazine is increasingly used in clinical practice as the first choice in hyperkinetic movement disorders, even if only one study fulfilled the selection criteria in the present review. Although the study by Heggarty and Wright suggested some promising effects of tetrabenazine on upper limb function and patient-reported daily activities, 44 it has some limitations which have already been highlighted by the authors themselves (classified as 'weak' for study conduct quality). Firstly, children allocated to tetrabenazine first had higher pretreatment scores than those receiving placebo first. Secondly, treatment was administered for only 2 weeks before patients were reversed to the other arm of treatment, and this too-short treatment time might have had a role in the lack of significant changes. Finally, the authors did not use valid and reliable disease-specific outcome measures, and they were not able to exclude a learning effect. Levodopa showed controversial results in the two studies reported, 40, 41 despite the fact that it has been considered one of the first approaches in childhood dystonia. This might be explained on the basis of the different drug dosages (higher in the study by Rosenthal et al.) 40 and/or of the outcome measures adopted. The study by Pozin et al. had a higher level of evidence and showed no differences between levodopa and placebo. 41 However, treatment only lasted 2 weeks, thus precluding the possibility of detecting noticeable changes in function. Despite these results, levodopa is recommended to be used as the first choice drug in particular conditions, especially when medical history and clinical features make the diagnosis of CP questionable. 48 Low-threshold levodopa trials (5-10mg/kg/ d for 4-8wks) are still recommended in clinical practice, in order not to miss a crucial treatable disorder, that is, doparesponsive dystonia, which can mimic CP.
Diazepam showed an unpredictable rate of response in the study by Angara and Whittaker. 42 Given its known muscle-relaxant effect, it could be more useful in patients with dystonia and hypertonia, especially if spasticity coexists.
The AACPDM has recently produced a Care Pathway for dystonia in CP, 49 mainly based on expert opinions (and supported by a systematic review of the literature, not yet available). For generalized dystonia, the proposed algorithm suggests the use of oral baclofen as first line treatment, followed by trihexyphenidyl as second-line treatment. This systematic review, based on studies specifically addressing dyskinetic CP, did not consider some drugs commonly used in the management of CP, such as oral baclofen or tizanidine. These drugs find their main indication in spastic forms of CP and, to our knowledge, no trials have been done to investigate their efficacy in dyskinetic CP. However, like benzodiazepines, they may be efficacious in reducing the hypertonic component of dystonia.
The same algorithm by AACPDM recommends the use of gabapentin when dystonia is associated with pain, and of clonidine and benzodiazepines when it is associated with disturbed sleep. Liow et al. studied gabapentin in a large group of children affected with secondary dystonia, 50 but this study has been excluded from qualitative analysis because of the small proportion of patients with dyskinetic CP in the total number of treated patients. No studies have been found on the effects of clonidine in dyskinetic CP.
CONCLUSION
The updated available evidence, as highlighted in the present systematic review, does not support any therapeutic algorithm with a hierarchical order of recommended drugs in the management of dyskinetic CP, regardless of its clinical phenotype, 48, 51 at any of the different levels of ICF. This lack of evidence is at least partially due to the inconsistency of classifications of patients and of outcome measures used in the reviewed studies. On the basis of our findings, it is paramount to design new pharmacological trials, both with drugs already available in clinical practice and with novel medicinal products.
Limited duration of treatment and possibly inadequate dose, particularly when considering the different pharmacokinetics and pharmacodynamics of oral medications in childhood, may be a common limitation in the detection of possible effects among the reviewed studies. This should also be taken into account when designing future clinical trials. Further well-designed, randomized, doubleblind, placebo-controlled pharmacological trials, optimized for different age groups, and based on valid, reliable, and disease-specific rating scales are strongly needed. The hypothesis to compare different oral treatments should also be tested in future trials. Patients should be included according to the most recent definition of CP and its subgroups, keeping in mind that classification in dystonic, choreoathetotic, and mixed forms would be fundamental to study effects of medications in dyskinetic CP. Furthermore, the aetiology of the disorder has to be taken into account, avoiding the confusion of grouping different syndromes (e.g. dyskinetic CP with other forms of inherited or acquired dystonia). As patients with CP tend to have more severity and less functional capability at baseline, compared with patients with movement disorder with primary dystonia and/or chorea, the degree of improvement may not be as robust. In order to assess effects not only at the body structure and functions levels, but also at the activities and participation levels, primary and secondary outcome measures should be selected within the framework of the ICF.
Based on this systematic review, there is still no strong evidence to prove (or disprove) the efficacy of available oral drugs in dyskinetic CP. Beside the need of prospective well-designed trials to study these medications, future research should systematically investigate the efficacy of other therapeutic options, such as intrathecal baclofen and deep brain stimulation, possibly at an earlier age when treatment might be more effective, as suggested by emerging data. 8, 9, 12, 13 
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